Stereotaxis, Inc. (NASDAQ: STXS) announced today that it has entered into a new strategic collaboration with Biosense Webster, Inc. related to Stereotaxis' rapidly growing Odyssey™ Solutions. This agreement marks the broadest and most committed cooperative agreement around Odyssey to date.
Under the new agreement, Stereotaxis has granted Biosense Webster global, non-exclusive rights to resell Stereotaxis' Odyssey products, including the market leading Odyssey Vision and Odyssey Cinema™ products for electrophysiology (EP) information management. Odyssey Vision provides unprecedented control of the entire interventional lab as one system with a consolidated view of patient information in a single display. Odyssey Cinema delivers real-time, remote viewing of live and recorded cases from a laptop anywhere in the world. Cinema supports the delivery of lab information over an Odyssey Network to revolutionize the way remote proctoring and education is delivered on a global basis. Stereotaxis' Odyssey business has grown rapidly in recent years, and now supports mission-critical interventional procedures with more than 170 systems sold worldwide in 24 countries.
Biosense Webster intends to sell and deploy Odyssey products in EP labs equipped with its CARTO® 3 platform, an advanced three-dimensional imaging technology used by electrophysiologists for the treatment of cardiac arrhythmias. The integrated solutions from both companies are expected to drive improved care and enhanced performance for EP practices worldwide.
"The interest in Odyssey continues to grow at an impressive rate," said Michael P. Kaminski, Stereotaxis President and CEO. "We are very enthusiastic about the opportunity to broaden our strong relationship with Biosense Webster, and share the common goal of establishing the Odyssey Network as the standard of care for interventional case data management and communication."
By leveraging Odyssey's unique clinical capabilities, Stereotaxis and Biosense Webster intend to transform EP labs into a streamlined workflow environment that is optimized to deliver patient care even under the most demanding situations. The CARTO® 3 System is the latest generation Biosense Webster offering for use by electrophysiologists in treating cardiac arrhythmias, such as atrial fibrillation. Atrial fibrillation is the most common form of irregular heartbeat, which affects more than 20 million patients worldwide and is the leading cause of stroke among people over 65 years old.
In addition to deploying Odyssey solutions within the hospital clinical environment, Stereotaxis and Biosense Webster will work together to pioneer an industry-first, remote clinical support model which utilizes the Odyssey platform. Biosense Webster intends to leverage Odyssey solutions to uniquely support its customers through real-time, remote access to Biosense Webster's best-in-class clinical support specialists. This new capability has the potential of enabling Biosense Webster to deliver a highly efficient and cost-effective telepresence support solution for customers around the world.
"Biosense Webster has a long track record of providing innovative solutions to deliver world-class customer support," said Mr. Kaminski. "We believe that the use of Odyssey for delivering virtually present clinical support will represent a paradigm shift in the industry to become a critical element of future clinical support."
Lifetime risk of atrial fibrillation rises to nearly 31% in recent decade